This review examines the relationship of endogenous TPO in health and disease to provide clues for therapeutic intervention with exogenous recombinant Mpl ligands.
May guide recombinant Mpl ligand development in thrombocytopenia; leaves open optimal strategies pending prospective trials.
The factor which is the primary regulator of megakaryocyte and platelet production has recently been identified as the ligand for the receptor Mpl. This discovery has resulted in substantial advances in our understanding of platelet homeostasis. The access to new experimental reagents has enabled studies of the endogenous circulating form of this ligand, endogenous thrombopoietin, in normal individuals and in patients with altered platelet numbers. The relationship of endogenous TPO in health and disease will be examined with consideration of the implications for successful therapeutic intervention with exogenous recombinant Mpl ligands in selected settings.
No takes yet. Share an insight, caveat, or question.
Janet L. Nichol (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: